{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T06:22:58Z","timestamp":1787725378916,"version":"build-2784847793"},"reference-count":140,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,6,26]],"date-time":"2025-06-26T00:00:00Z","timestamp":1750896000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,6,26]],"date-time":"2025-06-26T00:00:00Z","timestamp":1750896000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"National Institute of Allergy and Infectious Diseases (NIAID) or the National Institute of Health","award":["T32 AI157855"],"award-info":[{"award-number":["T32 AI157855"]}]},{"DOI":"10.13039\/100008374","name":"Center for AIDS Research, Emory University","doi-asserted-by":"publisher","award":["P30AI050409"],"award-info":[{"award-number":["P30AI050409"]}],"id":[{"id":"10.13039\/100008374","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008374","name":"Center for AIDS Research, Emory University","doi-asserted-by":"publisher","award":["P30AI050409"],"award-info":[{"award-number":["P30AI050409"]}],"id":[{"id":"10.13039\/100008374","id-type":"DOI","asserted-by":"publisher"}]},{"name":"National Institute on Aging (NIA) of the NIH","award":["K23AG084415"],"award-info":[{"award-number":["K23AG084415"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr HIV\/AIDS Rep"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s11904-025-00743-2","type":"journal-article","created":{"date-parts":[[2025,6,26]],"date-time":"2025-06-26T03:22:29Z","timestamp":1750908149000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["A Guide to the Evolving Clinical Landscape of Low-Level Viremia Among Persons with HIV in the Modern Treatment Era"],"prefix":"10.1007","volume":"22","author":[{"given":"Amalia","family":"Aldredge","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corrina","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anandi N.","family":"Sheth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren F.","family":"Collins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,26]]},"reference":[{"key":"743_CR1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI180075","volume":"134","author":"E Mihealsick","year":"2024","unstructured":"Mihealsick E, Word A, Scully EP. The impact of sex on HIV immunopathogenesis and therapeutic interventions. J Clin Invest. 2024;134:e180075.","journal-title":"J Clin Invest"},{"key":"743_CR2","unstructured":"Virological Failure [Internet]. EACS Guidelines. [cited 2024 Jan 24]. Available from: https:\/\/eacs.sanfordguide.com\/art\/eacs-virological-failure."},{"key":"743_CR3","unstructured":"Consolidated guidelines on HIV prevention, testing, treatment, service delivery and monitoring: recommendations for a public health approach [Internet]. Geneva: World Health Organization; 2021 [cited 2024 Jan 24]. Available from: http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK572729\/."},{"key":"743_CR4","unstructured":"Management of people with HIV and antiretroviral therapy experience [Internet]. Guidelines for the use of antiretroviral angents in adults and adolescents with HIV. 2024 [cited 2024 Nov 21]. Available from: https:\/\/clinicalinfo.hiv.gov\/en\/guidelines\/hiv-clinical-guidelines-adult-and-adolescent-arv\/virologic-failure."},{"key":"743_CR5","unstructured":"Low-level HIV viremia: definitions, predictors, mechanisms, and clinical outcomes. The Ontario HIV Treatment Network [Internet]. 2024 [cited 2024 May 1]. Available from: https:\/\/www.ohtn.on.ca\/rapid-response-low-level-hiv-viremia-definitions-predictors-mechanisms-and-clinical-outcomes\/."},{"key":"743_CR6","doi-asserted-by":"publisher","first-page":"e333","DOI":"10.1016\/S2352-3018(24)00063-8","volume":"11","author":"A Esteban-Cantos","year":"2024","unstructured":"Esteban-Cantos A, Montejano R, Pinto-Mart\u00ednez A, Rodr\u00edguez-Centeno J, Pulido F, Arribas JR. Non-suppressible viraemia during HIV-1 therapy: a challenge for clinicians. The Lancet HIV. 2024;11:e333\u201340.","journal-title":"The Lancet HIV"},{"key":"743_CR7","doi-asserted-by":"publisher","first-page":"3585","DOI":"10.1128\/AAC.00076-14","volume":"58","author":"P Ryscavage","year":"2014","unstructured":"Ryscavage P, Kelly S, Li JZ, Harrigan PR, Taiwo B. Significance and clinical management of persistent low-level viremia and very-low-level viremia in HIV-1-infected patients. Antimicrob Agents Chemother. 2014;58:3585\u201398.","journal-title":"Antimicrob Agents Chemother"},{"key":"743_CR8","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1089\/aid.2015.0102","volume":"31","author":"A Calcagno","year":"2015","unstructured":"Calcagno A, Motta I, Ghisetti V, Lo Re S, Allice T, Marinaro L, et al. HIV-1 very Low level viremia is associated with virological failure in highly active antiretroviral treatment-treated patients. AIDS Res Hum Retrovir. 2015;31:999\u20131008.","journal-title":"AIDS Res Hum Retrovir"},{"key":"743_CR9","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1177\/2325957416680028","volume":"16","author":"E Helou","year":"2017","unstructured":"Helou E, Shenoi S, Kyriakides T, Landry M-L, Kozal M, Barakat LA. Characterizing patients with very-low-level HIV viremia: a community-based study. J Int Assoc Provid AIDS Care. 2017;16:261\u20136.","journal-title":"J Int Assoc Provid AIDS Care"},{"key":"743_CR10","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1097\/QAI.0b013e3182567a57","volume":"60","author":"F Maggiolo","year":"2012","unstructured":"Maggiolo F, Callegaro A, Cologni G, Bernardini C, Velenti D, Gregis G, et al. Ultrasensitive assessment of residual low-level HIV viremia in HAART-treated patients and risk of virological failure. J Acquir Immune Defic Syndr. 2012;60:473\u201382.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"743_CR11","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.ijid.2021.02.045","volume":"105","author":"G-J Chen","year":"2021","unstructured":"Chen G-J, Sun H-Y, Chang S-Y, Cheng A, Huang Y-S, Huang S-H, et al. Incidence and impact of low-level viremia among people living with HIV who received protease inhibitor- or dolutegravir-based antiretroviral therapy. Int J Infect Dis. 2021;105:147\u201351.","journal-title":"Int J Infect Dis"},{"key":"743_CR12","doi-asserted-by":"publisher","first-page":"1967","DOI":"10.1097\/00002030-200209270-00017","volume":"16","author":"G Greub","year":"2002","unstructured":"Greub G, Cozzi-Lepri A, Ledergerber B, Staszewski S, Perrin L, Miller V, et al. Intermittent and sustained low-level HIV viral rebound in patients receiving potent antiretroviral therapy. AIDS. 2002;16:1967\u20139.","journal-title":"AIDS"},{"key":"743_CR13","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1177\/135965350801300707","volume":"13","author":"AM Geretti","year":"2008","unstructured":"Geretti AM, Smith C, Haberl A, Garcia-Diaz A, Nebbia G, Johnson M, et al. Determinants of virological failure after successful viral load suppression in first-line highly active antiretroviral therapy. Antivir Ther. 2008;13:927\u201336.","journal-title":"Antivir Ther"},{"key":"743_CR14","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1093\/jac\/dkm516","volume":"61","author":"P Garcia-Gasco","year":"2008","unstructured":"Garcia-Gasco P, Maida I, Blanco F, Barreiro P, Martin-Carbonero L, Vispo E, et al. Episodes of low-level viral rebound in HIV-infected patients on antiretroviral therapy: frequency, predictors and outcome. J Antimicrob Chemother. 2008;61:699\u2013704.","journal-title":"J Antimicrob Chemother"},{"key":"743_CR15","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.1093\/infdis\/jis104","volume":"205","author":"JT Grennan","year":"2012","unstructured":"Grennan JT, Loutfy MR, Su D, Harrigan PR, Cooper C, Klein M, et al. Magnitude of Virologic blips is associated with a higher risk for virologic rebound in HIV-infected individuals: a recurrent events analysis. J Infect Dis. 2012;205:1230\u20138.","journal-title":"J Infect Dis"},{"key":"743_CR16","doi-asserted-by":"publisher","first-page":"2919","DOI":"10.1080\/21505594.2021.2004743","volume":"12","author":"C Crespo-Bermejo","year":"2021","unstructured":"Crespo-Bermejo C, de Arellano ER, Lara-Aguilar V, Valle-Millares D, G\u00f3mez-Lus ML, Madrid R, et al. Persistent low-level viremia in persons living with HIV undertreatment: An unresolved status. Virulence. 2021;12:2919\u201331.","journal-title":"Virulence."},{"key":"743_CR17","doi-asserted-by":"publisher","first-page":"31","DOI":"10.4103\/ijstd.IJSTD_34_20","volume":"42","author":"A Patel","year":"2021","unstructured":"Patel A, Patel K, Pujari S, Patel J, Kumar A. Virological outcome and frequency of low-level viremia in patients receiving generic dolutegravir-containing regimen at a large tertiary care clinic in Western India. Indian J Sex Transm Dis. 2021;42:31.","journal-title":"Indian J Sex Transm Dis"},{"key":"743_CR18","doi-asserted-by":"publisher","first-page":"405","DOI":"10.3390\/v16030405","volume":"16","author":"M Underwood","year":"2024","unstructured":"Underwood M, Urbaityte R, Wang R, Horton J, Oyee J, Wynne B, et al. Dolutegravir + lamivudine vs. Dolutegravir + Tenofovir Disoproxil fumarate\/Emtricitabine: very-low-level HIV-1 replication through 144 weeks in the GEMINI-1 and GEMINI-2 studies. Viruses. 2024;16:405.","journal-title":"Viruses."},{"key":"743_CR19","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1111\/hiv.13541","volume":"25","author":"S El\u00e9n","year":"2024","unstructured":"El\u00e9n S, Bj\u00f6rkman P, Zazzi M, B\u00f6hm M, Bernal E, S\u00f6nnerborg A, et al. Low-level HIV viraemia during antiretroviral therapy: longitudinal patterns and predictors of viral suppression. HIV Medicine. 2024;25:107\u201316.","journal-title":"HIV Medicine."},{"key":"743_CR20","doi-asserted-by":"publisher","first-page":"2383","DOI":"10.3389\/fmicb.2019.02383","volume":"10","author":"JL Jacobs","year":"2019","unstructured":"Jacobs JL, Halvas EK, Tosiano MA, Mellors JW. Persistent HIV-1 viremia on antiretroviral therapy: measurement and mechanisms. Front Microbiol. 2019;10:2383.","journal-title":"Front Microbiol"},{"key":"743_CR21","doi-asserted-by":"publisher","first-page":"3212","DOI":"10.1038\/s41591-023-02611-1","volume":"29","author":"A Mohammadi","year":"2023","unstructured":"Mohammadi A, Etemad B, Zhang X, Li Y, Bedwell GJ, Sharaf R, et al. Viral and host mediators of non-suppressible HIV-1 viremia. Nat Med. 2023;29:3212\u201323.","journal-title":"Nat Med"},{"key":"743_CR22","doi-asserted-by":"publisher","first-page":"1376144","DOI":"10.3389\/fmicb.2024.1376144","volume":"15","author":"X Sun","year":"2024","unstructured":"Sun X, Zhang H, Kong X, Li N, Zhang T, An M, et al. Low-level viremia episodes appear to affect the provirus composition of the circulating cellular HIV reservoir during antiretroviral therapy. Front Microbiol. 2024;15:1376144.","journal-title":"Front Microbiol"},{"key":"743_CR23","doi-asserted-by":"publisher","first-page":"ofu119","DOI":"10.1093\/ofid\/ofu119","volume":"2","author":"C Konstantopoulos","year":"2015","unstructured":"Konstantopoulos C, Ribaudo H, Ragland K, Bangsberg DR, Li JZ. Antiretroviral regimen and suboptimal medication adherence are associated with low-level human immunodeficiency virus viremia. Open Forum Infect Dis. 2015;2:ofu119.","journal-title":"Open Forum Infect Dis"},{"key":"743_CR24","doi-asserted-by":"publisher","first-page":"ofab463","DOI":"10.1093\/ofid\/ofab463","volume":"8","author":"JR Castillo-Mancilla","year":"2021","unstructured":"Castillo-Mancilla JR, Morrow M, Coyle RP, Coleman SS, Zheng J-H, Ellison L, et al. Low-level viremia is associated with cumulative adherence to antiretroviral therapy in persons with HIV. Open Forum Infect Dis. 2021;8:ofab463.","journal-title":"Open Forum Infect Dis"},{"key":"743_CR25","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1097\/QAD.0000000000000123","volume":"28","author":"JZ Li","year":"2014","unstructured":"Li JZ, Gallien S, Ribaudo H, Heisey A, Bangsberg DR, Kuritzkes DR. Incomplete adherence to antiretroviral therapy is associated with higher levels of residual HIV-1 viremia. AIDS. 2014;28:181\u20136.","journal-title":"AIDS."},{"key":"743_CR26","doi-asserted-by":"publisher","first-page":"e0142923","DOI":"10.1371\/journal.pone.0142923","volume":"10","author":"G Leierer","year":"2015","unstructured":"Leierer G, Grabmeier-Pfistershammer K, Steuer A, Geit M, Sarcletti M, Haas B, et al. Factors associated with low-level viraemia and virological failure: results from the Austrian HIV cohort study. PLoS ONE. 2015;10:e0142923.","journal-title":"PLoS ONE"},{"key":"743_CR27","doi-asserted-by":"publisher","first-page":"91","DOI":"10.2147\/POR.S127974","volume":"8","author":"F Maggiolo","year":"2017","unstructured":"Maggiolo F, Di Filippo E, Comi L, Callegaro A, Colombo G, Di Matteo S, et al. Reduced adherence to antiretroviral therapy is associated with residual low-level viremia. POR. 2017;8:91\u20137.","journal-title":"POR."},{"key":"743_CR28","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1093\/infdis\/jis502","volume":"206","author":"AO Pasternak","year":"2012","unstructured":"Pasternak AO, de Bruin M, Jurriaans S, Bakker M, Berkhout B, Prins JM, et al. Modest nonadherence to antiretroviral therapy promotes residual HIV-1 replication in the absence of Virological rebound in plasma. J Infect Dis. 2012;206:1443\u201352.","journal-title":"J Infect Dis"},{"key":"743_CR29","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1086\/523704","volume":"196","author":"TJ Podsadecki","year":"2007","unstructured":"Podsadecki TJ, Vrijens BC, Tousset EP, Rode RA, Hanna GJ. Decreased adherence to antiretroviral therapy observed prior to transient human immunodeficiency virus type 1 viremia. J Infect Dis. 2007;196:1773\u20138.","journal-title":"J Infect Dis"},{"key":"743_CR30","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1080\/09540121.2020.1806198","volume":"33","author":"J Goupil De Bouill\u00e9","year":"2021","unstructured":"Goupil De Bouill\u00e9 J, Collignon M, Capsec J, Guillon L, Le Moal G, Barin F, et al. Low-level HIV viremia is associated with low antiretroviral prescription refill rates and social deprivation. AIDS Care. 2021;33:1445\u201350.","journal-title":"AIDS Care"},{"key":"743_CR31","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1097\/QAD.0000000000002588","volume":"34","author":"SC Inzaule","year":"2020","unstructured":"Inzaule SC, Bertagnolio S, Kityo CM, Siwale M, Akanmu S, Wellington M, et al. The relative contributions of HIV drug resistance, nonadherence and low-level viremia to viremic episodes on antiretroviral therapy in sub-Saharan Africa. AIDS. 2020;34:1559\u201366.","journal-title":"AIDS."},{"key":"743_CR32","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1111\/hiv.13568","volume":"25","author":"N Nanyeenya","year":"2024","unstructured":"Nanyeenya N, Nakanjako D, Makumbi F, Nakigozi G, Nalugoda F, Kigozi G, et al. Effectiveness of intensive adherence counselling in achieving an undetectable viral load among people on antiretroviral therapy with low-level viraemia in Uganda. HIV Medicine. 2024;25:245\u201353.","journal-title":"HIV Medicine"},{"key":"743_CR33","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1086\/382895","volume":"189","author":"LG Miller","year":"2004","unstructured":"Miller LG, Golin CE, Liu H, Hays RD, Hua J, Wenger NS, et al. No evidence of an association between transient HIV viremia (\u201cblips\u201d) and lower adherence to the antiretroviral medication regimen. J Infect Dis. 2004;189:1487\u201396.","journal-title":"J Infect Dis"},{"key":"743_CR34","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1093\/infdis\/jiy011","volume":"218","author":"M Gandhi","year":"2018","unstructured":"Gandhi M, Gandhi RT, Stefanescu A, Bosch RJ, Cyktor JC, Horng H, et al. Cumulative antiretroviral exposure measured in hair is not associated with measures of HIV persistence or inflammation among individuals on suppressive ART. J Infect Dis. 2018;218:234\u20138.","journal-title":"J Infect Dis"},{"key":"743_CR35","doi-asserted-by":"crossref","unstructured":"Coyle RP, Morrow M, Mann SC, Mainella V, Ellis SL, Schwab S, et al. Tenofovir-diphosphate and Emtricitabine-triphosphate adherence benchmarks in dried blood spots for persons with HIV receiving Tenofovir Alafenamide and Emtricitabine-based antiretroviral therapy (QUANTI-TAF). Clin Infect Dis. 2024:ciae212.","DOI":"10.1093\/cid\/ciae212"},{"key":"743_CR36","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1089\/aid.2014.0060","volume":"31","author":"S Baroncelli","year":"2015","unstructured":"Baroncelli S, Pirillo MF, Galluzzo CM, Antoni AD, Ladisa N, Francisci D, et al. Rate and determinants of residual viremia in multidrug-experienced patients successfully treated with Raltegravir-based regimens. AIDS Res Hum Retrovir. 2015;31:71\u20137.","journal-title":"AIDS Res Hum Retrovir"},{"key":"743_CR37","doi-asserted-by":"publisher","first-page":"2981","DOI":"10.1093\/jac\/dkaa273","volume":"75","author":"R Palich","year":"2020","unstructured":"Palich R, Wirden M, Peytavin G, L\u00ea M-P, Seang S, Abdi B, et al. Persistent low-level viraemia in antiretroviral treatment-experienced patients is not linked to viral resistance or inadequate drug concentrations. J Antimicrob Chemother. 2020;75:2981\u20135.","journal-title":"J Antimicrob Chemother"},{"key":"743_CR38","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1111\/hiv.13251","volume":"23","author":"R Bai","year":"2022","unstructured":"Bai R, Lv S, Hua W, Su B, Wang S, Shao Y, et al. Factors associated with human immunodeficiency virus-1 low-level viremia and its impact on virological and immunological outcomes: a retrospective cohort study in Beijing, China. HIV Medicine. 2022;23:72\u201383.","journal-title":"HIV Medicine"},{"key":"743_CR39","doi-asserted-by":"publisher","first-page":"e0268540","DOI":"10.1371\/journal.pone.0268540","volume":"17","author":"H Brattg\u00e5rd","year":"2022","unstructured":"Brattg\u00e5rd H, Bj\u00f6rkman P, Nowak P, Treutiger CJ, Gissl\u00e9n M, Elvstam O. Factors associated with low-level viraemia in people with HIV starting antiretroviral therapy: a Swedish observational study. PLoS ONE. 2022;17:e0268540.","journal-title":"PLoS ONE"},{"key":"743_CR40","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s12879-023-08906-5","volume":"24","author":"X Lao","year":"2024","unstructured":"Lao X, Zhang H, Deng M, Li Q, Xiao Q, He L, et al. Incidence of low-level viremia and its impact on virologic failure among people living with HIV who started an integrase strand transfer inhibitors: a longitudinal cohort study. BMC Infect Dis. 2024;24:8.","journal-title":"BMC Infect Dis"},{"key":"743_CR41","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1097\/JCMA.0000000000000812","volume":"85","author":"C-T Lee","year":"2022","unstructured":"Lee C-T, Chen H-P, Lin H-H, Ke M-Y, Wu P-F. The influence of low-level viremia on CD4+ cell count in human immunodeficiency virus\u2013infected patients. J Chin Med Assoc. 2022;85:1126\u201330.","journal-title":"J Chin Med Assoc"},{"key":"743_CR42","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1002\/jmv.23553","volume":"85","author":"J Saison","year":"2013","unstructured":"Saison J, Tardy J-C, Scholtes C, Icard V, Trabaud M-A, Perpoint T, et al. Low-level viremia is associated with non-B subtypes in patients infected with HIV with virological success following HAART introduction. J Med Virol. 2013;85:953\u20138.","journal-title":"J Med Virol"},{"key":"743_CR43","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1111\/hiv.13265","volume":"23","author":"H \u00c1lvarez","year":"2022","unstructured":"\u00c1lvarez H, Rava M, Mart\u00ednez C, Portilla J, Peraire J, Rivero A, et al. Predictors of low-level HIV viraemia and virological failure in the era of integrase inhibitors: a Spanish nationwide cohort. HIV Medicine. 2022;23:825\u201336.","journal-title":"HIV Medicine."},{"key":"743_CR44","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1093\/cid\/ciad219","volume":"77","author":"H \u00c1lvarez","year":"2023","unstructured":"\u00c1lvarez H, Mocroft A, Ryom L, Neesgaard B, Edwards S, Svedhem V, et al. Plasma human immunodeficiency virus 1 RNA and CD4+ T-cell counts are determinants of virological nonsuppression outcomes with initial integrase inhibitor-based regimens: a prospective RESPOND cohort study. Clin Infect Dis. 2023;77:593\u2013605.","journal-title":"Clin Infect Dis"},{"key":"743_CR45","doi-asserted-by":"publisher","first-page":"165","DOI":"10.3851\/IMP2815","volume":"20","author":"N Boillat-Blanco","year":"2015","unstructured":"Boillat-Blanco N, Darling KE, Schoni-Affolter F, Vuichard D, Rougemont M, Fulchini R, et al. Virological outcome and management of persistent low-level viraemia in HIV-1-infected patients: 11 years of the Swiss HIV cohort study. Antivir Ther. 2015;20:165\u201375.","journal-title":"Antivir Ther"},{"key":"743_CR46","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2022.106631","volume":"60","author":"G-J Chen","year":"2022","unstructured":"Chen G-J, Sun H-Y, Chen L-Y, Hsieh S-M, Sheng W-H, Liu W-D, et al. Low-level viraemia and virologic failure among people living with HIV who received maintenance therapy with co-formulated bictegravir, emtricitabine and tenofovir alafenamide versus dolutegravir-based regimens. Int J Antimicrob Agents. 2022;60:106631.","journal-title":"Int J Antimicrob Agents"},{"key":"743_CR47","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1093\/cid\/ciy989","volume":"69","author":"A Esber","year":"2019","unstructured":"Esber A, Polyak C, Kiweewa F, Maswai J, Owuoth J, Maganga L, et al. Persistent Low-level viremia predicts subsequent Virologic failure: is it time to change the third 90? Clin Infect Dis. 2019;69:805\u201312.","journal-title":"Clin Infect Dis"},{"key":"743_CR48","doi-asserted-by":"publisher","first-page":"204993612412422","DOI":"10.1177\/20499361241242240","volume":"11","author":"O Onwah","year":"2024","unstructured":"Onwah O, Nwanja E, Akpan U, Toyo O, Nwangeneh C, Oyawola B, et al. Prevalence and predictors of persistent low-level HIV viraemia: a retrospective cohort study among people receiving dolutegravir-based antiretroviral therapy in southern Nigeria. Ther Adv Infect. 2024;11:20499361241242240.","journal-title":"Ther Adv Infect"},{"key":"743_CR49","doi-asserted-by":"publisher","first-page":"2145","DOI":"10.1093\/cid\/ciz129","volume":"69","author":"C Joya","year":"2019","unstructured":"Joya C, Won SH, Schofield C, Lalani T, Maves RC, Kronmann K, et al. Persistent Low-level viremia while on antiretroviral therapy is an independent risk factor for virologic failure. Clin Infect Dis. 2019;69:2145\u201352.","journal-title":"Clin Infect Dis"},{"key":"743_CR50","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.939261","volume":"9","author":"J An","year":"2022","unstructured":"An J, Lao Y, Tang S, Lou J, Li T, Dong X. The impact of low-level viraemia on virological failure\u2014results from a multicenter HIV antiretroviral therapy cohort study in Yunnan. China Front Med. 2022;9:939261.","journal-title":"China Front Med"},{"key":"743_CR51","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1111\/tmi.13951","volume":"29","author":"WM Han","year":"2024","unstructured":"Han WM, Broom J, Bopage R, Templeton DJ, Edmiston N, Petoumenos K, et al. Investigating rates and predictors of viral blips, low-level viraemia and virological failure in the Australian HIV observational database. Trop Med Int Health. 2024;29:42\u201356.","journal-title":"Trop Med Int Health"},{"key":"743_CR52","doi-asserted-by":"publisher","first-page":"e0279479","DOI":"10.1371\/journal.pone.0279479","volume":"18","author":"N Nanyeenya","year":"2023","unstructured":"Nanyeenya N, Chang LW, Kiwanuka N, Nasuuna E, Nakanjako D, Nakigozi G, et al. The association between low-level viraemia and subsequent viral non-suppression among people living with HIV\/AIDS on antiretroviral therapy in Uganda. PLoS ONE. 2023;18:e0279479.","journal-title":"PLoS ONE"},{"key":"743_CR53","doi-asserted-by":"publisher","DOI":"10.1002\/jia2.26200","volume":"27","author":"JG Rosen","year":"2024","unstructured":"Rosen JG, Ssekubugu R, Chang LW, Ssempijja V, Galiwango RM, Ssekasanvu J, et al. Temporal dynamics and drivers of durable HIV viral load suppression and persistent high- and low-level viraemia during universal test and treat scale-up in Uganda: a population-based study. J Int AIDS Soc. 2024;27:e26200.","journal-title":"J Int AIDS Soc"},{"key":"743_CR54","doi-asserted-by":"publisher","first-page":"e26","DOI":"10.1016\/S2468-2667(16)30002-0","volume":"1","author":"LS Burch","year":"2016","unstructured":"Burch LS, Smith CJ, Anderson J, Sherr L, Rodger AJ, O\u2019Connell R, et al. Socioeconomic status and treatment outcomes for individuals with HIV on antiretroviral treatment in the UK: cross-sectional and longitudinal analyses. Lancet Public Health. 2016;1:e26\u201336.","journal-title":"Lancet Public Health"},{"key":"743_CR55","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1089\/aid.2023.0015","volume":"40","author":"F Lombardi","year":"2024","unstructured":"Lombardi F, Bruzzesi E, Bouba YR, Di Carlo D, Costabile V, Ranzenigo M, et al. Factors associated with low-level viremia in people living with HIV in the Italian antiviral response cohort analysis cohort: a case\u2013control study. AIDS Res Hum Retrovir. 2024;40:80\u20139.","journal-title":"AIDS Res Hum Retrovir"},{"key":"743_CR56","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1097\/QAI.0000000000002898","volume":"89","author":"S Dijkstra","year":"2022","unstructured":"Dijkstra S, Hofstra LM, Mudrikova T, Wensing AMJ, Oomen PGA, Hoepelman AIM, et al. Lower incidence of HIV-1 blips observed during integrase inhibitor\u2013based combination antiretroviral therapy. JAIDS Journal of Acquired Immune Deficiency Syndromes. 2022;89:575\u201382.","journal-title":"JAIDS Journal of Acquired Immune Deficiency Syndromes"},{"key":"743_CR57","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1093\/cid\/ciac762","volume":"76","author":"O Elvstam","year":"2023","unstructured":"Elvstam O, Malmborn K, El\u00e9n S, Marrone G, Garc\u00eda F, Zazzi M, et al. Virologic failure following low-level viremia and viral blips during antiretroviral therapy: results from a European multicenter cohort. Clin Infect Dis. 2023;76:25\u201331.","journal-title":"Clin Infect Dis"},{"key":"743_CR58","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2022.944990","volume":"10","author":"D Yuan","year":"2022","unstructured":"Yuan D, Zhou Y, Shi L, Liu Y, Lu J, Chen J, et al. HIV-1 drug resistance profiles of Low-level viremia patients and factors associated with the treatment effect of ART-treated patients: a cross-sectional study in Jiangsu. China Front Public Health. 2022;10:944990.","journal-title":"China Front Public Health"},{"key":"743_CR59","doi-asserted-by":"publisher","first-page":"182","DOI":"10.3390\/v16020182","volume":"16","author":"AJ Stam","year":"2024","unstructured":"Stam AJ, Buchholtz NVEJ, Bierman WFW, Van Crevel R, Hoepelman AIM, Claassen MAA, et al. Dynamics of low-level viremia and immune activation after switching to a Darunavir-based regimen. Viruses. 2024;16:182.","journal-title":"Viruses."},{"key":"743_CR60","doi-asserted-by":"publisher","first-page":"e1003325","DOI":"10.1371\/journal.pmed.1003325","volume":"17","author":"A Amstutz","year":"2020","unstructured":"Amstutz A, Nsakala BL, Vanobberghen F, Muhairwe J, Glass TR, Namane T, et al. Switch to second-line versus continued first-line antiretroviral therapy for patients with low-level HIV-1 viremia: an open-label randomized controlled trial in Lesotho. PLoS Med. 2020;17:e1003325.","journal-title":"PLoS Med"},{"key":"743_CR61","doi-asserted-by":"publisher","first-page":"ofae013","DOI":"10.1093\/ofid\/ofae013","volume":"11","author":"M Kohler","year":"2024","unstructured":"Kohler M, Brown JA, Tschumi N, Lerotholi M, Motaboli L, Mokete M, et al. Clinical relevance of human immunodeficiency virus Low-level viremia in the Dolutegravir era: data from the viral load cohort north-East Lesotho (VICONEL). Open Forum Infect Dis. 2024;11:ofae013.","journal-title":"Open Forum Infect Dis"},{"key":"743_CR62","volume":"63","author":"A Aoko","year":"2023","unstructured":"Aoko A, Pals S, Ngugi T, Katiku E, Joseph R, Basiye F, et al. Retrospective longitudinal analysis of low-level viremia among HIV-1 infected adults on antiretroviral therapy in Kenya eClinicalMedicine. 2023;63:102166.","journal-title":"Retrospective longitudinal analysis of low-level viremia among HIV-1 infected adults on antiretroviral therapy in Kenya eClinicalMedicine"},{"key":"743_CR63","doi-asserted-by":"publisher","first-page":"e1815","DOI":"10.1016\/S2214-109X(22)00413-2","volume":"10","author":"HM Chun","year":"2022","unstructured":"Chun HM, Abutu A, Milligan K, Ehoche A, Shiraishi RW, Odafe S, et al. Low-level viraemia among people living with HIV in Nigeria: a retrospective longitudinal cohort study. Lancet Glob Health. 2022;10:e1815\u201324.","journal-title":"Lancet Glob Health"},{"key":"743_CR64","doi-asserted-by":"publisher","DOI":"10.1002\/jia2.26394","volume":"27","author":"KA Christopoulos","year":"2024","unstructured":"Christopoulos KA, Smith MB, Pareek P, Dawdani A, Erguera XA, Dance KV, et al. Learning from the first: a qualitative study of the psychosocial benefits and treatment burdens of long-acting cabotegravir\/rilpivirine among early adopters in three U.S. clinics. J Int AIDS Soc. 2024;27:e26394.","journal-title":"J Int AIDS Soc"},{"key":"743_CR65","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1097\/QAI.0000000000003320","volume":"95","author":"L Hill","year":"2024","unstructured":"Hill L, Kenney S, Patel N, Yin J, Abulhosn K, Karim A, et al. Predictors of post-switch viremia in people with HIV on injectable Cabotegravir\/Rilpivirine. JAIDS Journal of Acquired Immune Deficiency Syndromes. 2024;95:90\u20136.","journal-title":"JAIDS Journal of Acquired Immune Deficiency Syndromes."},{"key":"743_CR66","doi-asserted-by":"crossref","unstructured":"Guti\u00e9rrez F, Fern\u00e1ndez-Gonz\u00e1lez M, Ledesma C, Losada-Echeberr\u00eda M, Barraj\u00f3n-Catal\u00e1n E, Garc\u00eda-Abell\u00e1n J, et al. Virological history predicts non-sustained viral suppression with long-acting Cabotegravir and Rilpivirine therapy, independent of pharmacokinetic parameters. Clin Infect Dis. 2024:ciae475.","DOI":"10.1093\/cid\/ciae475"},{"key":"743_CR67","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1093\/jpids\/piy041","volume":"8","author":"R Pereira","year":"2019","unstructured":"Pereira R, Ludwig DA, Mathew S, Flores C, Dominguez S, Gonzalez I, et al. Predicting viral failure in human immunodeficiency virus perinatally infected youth with persistent Low-level viremia on highly active antiretroviral therapy. J Pediatric Infect Dis Soc. 2019;8:303\u20139.","journal-title":"J Pediatric Infect Dis Soc"},{"key":"743_CR68","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2023\/8961372","volume":"2023","author":"MM Nzivo","year":"2023","unstructured":"Nzivo MM, Waruhiu CN, Kang\u2019ethe JM, Budambula NLM. HIV virologic failure among patients with persistent Low-level viremia in Nairobi, Kenya: it is time to review the >1000 Virologic failure threshold. Biomed Res Int. 2023;2023:1\u201310.","journal-title":"Biomed Res Int"},{"key":"743_CR69","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1097\/QAI.0000000000001678","volume":"78","author":"E Bernal","year":"2018","unstructured":"Bernal E, G\u00f3mez JM, Jarr\u00edn I, Cano A, Mu\u00f1oz A, Alcaraz A, et al. Low-level viremia is associated with clinical progression in HIV-infected patients receiving antiretroviral treatment. JAIDS Journal of Acquired Immune Deficiency Syndromes. 2018;78:329\u201337.","journal-title":"JAIDS Journal of Acquired Immune Deficiency Syndromes."},{"key":"743_CR70","doi-asserted-by":"publisher","first-page":"2005","DOI":"10.1097\/QAD.0000000000002306","volume":"33","author":"J Fleming","year":"2019","unstructured":"Fleming J, Mathews WC, Rutstein RM, Aberg J, Somboonwit C, Cheever LW, et al. Low-level viremia and virologic failure in persons with HIV infection treated with antiretroviral therapy. AIDS. 2019;33:2005\u201312.","journal-title":"AIDS."},{"key":"743_CR71","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/S1473-3099(17)30681-3","volume":"18","author":"LE Hermans","year":"2018","unstructured":"Hermans LE, Moorhouse M, Carmona S, Grobbee DE, Hofstra LM, Richman DD, et al. Effect of HIV-1 low-level viraemia during antiretroviral therapy on treatment outcomes in WHO-guided south African treatment programmes: a multicentre cohort study. Lancet Infect Dis. 2018;18:188\u201397.","journal-title":"Lancet Infect Dis"},{"key":"743_CR72","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.jgar.2022.02.007","volume":"29","author":"J-Y Hsu","year":"2022","unstructured":"Hsu J-Y, Sun H-Y, Hsieh T-W, Chang S-Y, Chuang Y-C, Huang Y-S, et al. Incidence of low-level viremia and its impact on virologic failure among people living with HIV-1 who switched to elvitegravir-based antiretroviral therapy. J Glob Antimicrob Resist. 2022;29:7\u201316.","journal-title":"J Glob Antimicrob Resist"},{"key":"743_CR73","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1093\/cid\/cit529","volume":"57","author":"C Laprise","year":"2013","unstructured":"Laprise C, de Pokomandy A, Baril J-G, Dufresne S, Trottier H. Virologic failure following persistent low-level viremia in a cohort of HIV-positive patients: results from 12 years of observation. Clin Infect Dis. 2013;57:1489\u201396.","journal-title":"Clin Infect Dis"},{"key":"743_CR74","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1111\/j.1468-1293.2006.00403.x","volume":"7","author":"S Sungkanuparph","year":"2006","unstructured":"Sungkanuparph S, Groger R, Overton E, Fraser V, Powderly W. Persistent low-level viraemia and virological failure in HIV-1-infected patients treated with highly active antiretroviral therapy. HIV Med. 2006;7:437\u201341.","journal-title":"HIV Med."},{"key":"743_CR75","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1097\/QAD.0000000000000544","volume":"29","author":"M-A Vandenhende","year":"2015","unstructured":"Vandenhende M-A, Ingle S, May M, Chene G, Zangerle R, Van Sighem A, et al. Impact of low-level viremia on clinical and virological outcomes in treated HIV-1-infected patients. AIDS. 2015;29:373\u201383.","journal-title":"AIDS."},{"key":"743_CR76","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.1097\/QAD.0000000000003990","volume":"38","author":"A Aldredge","year":"2024","unstructured":"Aldredge A, Mehta CC, Lahiri CD, Schneider MF, Alcaide ML, Anastos K, et al. Consequences of low-level viremia among women with HIV in the United States. AIDS. 2024;38:1829\u201338.","journal-title":"AIDS."},{"key":"743_CR77","doi-asserted-by":"publisher","first-page":"720","DOI":"10.3390\/v16050720","volume":"16","author":"OT Bareng","year":"2024","unstructured":"Bareng OT, Moyo S, Mudanga M, Sebina K, Koofhethile CK, Choga WT, et al. Low-level viremia among adults living with HIV on Dolutegravir-based first-line antiretroviral therapy is a predictor of Virological failure in Botswana. Viruses. 2024;16:720.","journal-title":"Viruses."},{"key":"743_CR78","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1111\/hiv.13250","volume":"23","author":"H Ding","year":"2022","unstructured":"Ding H, Xu J, Liu J, Wang Q, Kang J, Li X, et al. Outcomes of persistent low-level viremia among HIV patients on antiretroviral therapy: a prospective cohort study. HIV Medicine. 2022;23:64\u201371.","journal-title":"HIV Medicine."},{"key":"743_CR79","doi-asserted-by":"publisher","DOI":"10.1002\/jia2.25550","volume":"23","author":"T Sudjaritruk","year":"2020","unstructured":"Sudjaritruk T, Teeraananchai S, Kariminia A, Lapphra K, Kumarasamy N, Fong MS, et al. Impact of low-level viraemia on virological failure among Asian children with perinatally acquired HIV on first-line combination antiretroviral treatment: a multicentre, retrospective cohort study. J Intern AIDS Soc. 2020;23:e25550.","journal-title":"J Intern AIDS Soc"},{"key":"743_CR80","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1186\/s12879-020-4837-y","volume":"20","author":"T Zhang","year":"2020","unstructured":"Zhang T, Ding H, An M, Wang X, Tian W, Zhao B, et al. Factors associated with high-risk low-level viremia leading to virologic failure: 16-year retrospective study of a Chinese antiretroviral therapy cohort. BMC Infect Dis. 2020;20:147.","journal-title":"BMC Infect Dis"},{"key":"743_CR81","doi-asserted-by":"publisher","first-page":"232595822097981","DOI":"10.1177\/2325958220979817","volume":"19","author":"Z Gaifer","year":"2020","unstructured":"Gaifer Z, Boulassel M-R. Low-level viremia predicts virological failure in HIV-infected Omani patients receiving antiretroviral therapy. J Int Assoc Provid AIDS Care. 2020;19:232595822097981.","journal-title":"J Int Assoc Provid AIDS Care"},{"key":"743_CR82","doi-asserted-by":"publisher","first-page":"2659","DOI":"10.1093\/jac\/dkab220","volume":"76","author":"A Bangalee","year":"2021","unstructured":"Bangalee A, Hans L, Steegen K. Feasibility and clinical relevance of HIV-1 drug resistance testing in patients with low-level viraemia in South Africa. J Antimicrob Chemother. 2021;76:2659\u201365.","journal-title":"J Antimicrob Chemother"},{"key":"743_CR83","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1089\/aid.2022.0140","volume":"39","author":"B Cao","year":"2023","unstructured":"Cao B, Liu M, Jiang T, Yu Q, Yuan T, Ding P, et al. HIV-1 RNA and DNA genotyping drug resistance detection in patients with Low-level viremia in Liangshan, China. AIDS Res Hum Retroviruses. 2023;39:429\u201335.","journal-title":"AIDS Res Hum Retroviruses"},{"key":"743_CR84","doi-asserted-by":"publisher","first-page":"2938","DOI":"10.1093\/jac\/dkad334","volume":"78","author":"ABD Djiyou","year":"2023","unstructured":"Djiyou ABD, Penda CI, Madec Y, Ngondi GD, Moukoko A, Eboumbou CE, et al. Prevalence of HIV drug resistance among adolescents receiving ART in Cameroon with low- or high-level viraemia. J Antimicrob Chemother. 2023;78:2938\u201342.","journal-title":"J Antimicrob Chemother"},{"key":"743_CR85","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1080\/25787489.2020.1716159","volume":"20","author":"F Ferretti","year":"2019","unstructured":"Ferretti F, Mackie NE, Singh GKJ, Fox J, Kaye S, McClure MO, et al. Characterization of low level viraemia in HIV-infected patients receiving boosted protease inhibitor-based antiretroviral regimens. HIV Res Clin Pract. 2019;20:107\u201310.","journal-title":"HIV Res Clin Pract"},{"key":"743_CR86","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1093\/jac\/dkaa510","volume":"76","author":"S-W Kao","year":"2021","unstructured":"Kao S-W, Liu Z-H, Wu T-S, Ku SW-W, Tsai C-L, Shie S-S, et al. Prevalence of drug resistance mutations in HIV-infected individuals with low-level viraemia under combination antiretroviral therapy: an observational study in a tertiary hospital in northern Taiwan, 2017\u201319. J Antimicrob Chemother. 2021;76:722\u20138.","journal-title":"J Antimicrob Chemother"},{"key":"743_CR87","doi-asserted-by":"publisher","first-page":"4953","DOI":"10.2147\/IDR.S419610","volume":"16","author":"Y Lan","year":"2023","unstructured":"Lan Y, Ling X, Deng X, Lin Y, Li J, Li L, et al. Drug resistance profile among HIV-1 infections experiencing ART with Low-level viral load in Guangdong China during 2011\u20132022: a retrospective study. IDR. 2023;16:4953\u201364.","journal-title":"IDR."},{"key":"743_CR88","doi-asserted-by":"publisher","first-page":"6711","DOI":"10.2147\/IDR.S387215","volume":"15","author":"Q Li","year":"2022","unstructured":"Li Q, Yu F, Song C, Zhao H, Xiao Q, Lao X, et al. HIV-1 genotypic resistance testing using sanger and next-generation sequencing in adults with Low-level viremia in China. IDR. 2022;15:6711\u201322.","journal-title":"IDR."},{"key":"743_CR89","doi-asserted-by":"publisher","first-page":"10620","DOI":"10.1038\/s41598-024-60965-z","volume":"14","author":"J Liu","year":"2024","unstructured":"Liu J, Li C, Sun Y, Fu C, Wei S, Zhang X, et al. Characteristics of drug resistance mutations in ART-experienced HIV-1 patients with low-level viremia in Zhengzhou City. China Sci Rep. 2024;14:10620.","journal-title":"China Sci Rep"},{"key":"743_CR90","doi-asserted-by":"publisher","first-page":"4697","DOI":"10.2147\/IDR.S406188","volume":"16","author":"S Lv","year":"2023","unstructured":"Lv S, Sun L, Li T, Bai R, Dai M, Wang R, et al. Role of proviral HIV-1 DNA genotyping for people living with HIV (PLWH) who had low-level viremia while receiving antiretroviral therapy. IDR. 2023;16:4697\u2013706.","journal-title":"IDR."},{"key":"743_CR91","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcv.2020.104657","volume":"132","author":"C Villalobos","year":"2020","unstructured":"Villalobos C, Ceballos ME, Ferr\u00e9s M, Palma C. Drug resistance mutations in proviral DNA of HIV-infected patients with low level of viremia. J Clin Virol. 2020;132:104657.","journal-title":"J Clin Virol"},{"key":"743_CR92","doi-asserted-by":"publisher","first-page":"e36673","DOI":"10.1371\/journal.pone.0036673","volume":"7","author":"C Delaugerre","year":"2012","unstructured":"Delaugerre C, Gallien S, Flandre P, Mathez D, Amarsy R, Ferret S, et al. Impact of Low-level-viremia on HIV-1 drug-resistance evolution among antiretroviral treated-patients. PLoS One. 2012;7:e36673.","journal-title":"PLoS One"},{"key":"743_CR93","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1093\/cid\/ciu019","volume":"58","author":"A Gonzalez-Serna","year":"2014","unstructured":"Gonzalez-Serna A, Min JE, Woods C, Chan D, Lima VD, Montaner JSG, et al. Performance of HIV-1 drug resistance testing at Low-level viremia and its ability to predict future Virologic outcomes and viral evolution in treatment-naive individuals. Clin Infect Dis. 2014;58:1165\u201373.","journal-title":"Clin Infect Dis"},{"key":"743_CR94","doi-asserted-by":"publisher","first-page":"71","DOI":"10.4236\/wja.2013.32010","volume":"03","author":"MR Jordan","year":"2013","unstructured":"Jordan MR, Winsett J, Tiro A, Bau V, Berbara RS, Rowley C, et al. HIV drug resistance profiles and clinical outcomes in patients with viremia maintained at very low levels. WJA. 2013;03:71\u20138.","journal-title":"WJA."},{"key":"743_CR95","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1086\/651618","volume":"201","author":"NE Mackie","year":"2010","unstructured":"Mackie NE, Phillips AN, Kaye S, Booth C, Geretti A. Antiretroviral drug resistance in HIV-1-infected patients with low-level viremia. J Infect Dis. 2010;201:1303\u20137.","journal-title":"J Infect Dis"},{"key":"743_CR96","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1097\/QAD.0000000000000203","volume":"28","author":"LC Swenson","year":"2014","unstructured":"Swenson LC, Min JE, Woods CK, Cai E, Li JZ, Montaner JSG, et al. HIV drug resistance detected during low-level viraemia is associated with subsequent virologic failure. AIDS. 2014;28:1125\u201334.","journal-title":"AIDS."},{"key":"743_CR97","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1093\/infdis\/jir353","volume":"204","author":"B Taiwo","year":"2011","unstructured":"Taiwo B, Gallien S, Aga E, Ribaudo H, Haubrich R, Kuritzkes DR, et al. Antiretroviral drug resistance in HIV-1\u2013infected patients experiencing persistent Low-level viremia during first-line therapy. J Infect Dis. 2011;204:515\u201320.","journal-title":"J Infect Dis"},{"key":"743_CR98","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcv.2019.104255","volume":"123","author":"L Taramasso","year":"2020","unstructured":"Taramasso L, Magnasco L, Bruzzone B, Caligiuri P, Bozzi G, Mora S, et al. How relevant is the HIV low level viremia and how is its management changing in the era of modern ART? A large cohort analysis. J Clin Virol. 2020;123:104255.","journal-title":"J Clin Virol"},{"key":"743_CR99","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1093\/jac\/dkab025","volume":"76","author":"JA Brown","year":"2021","unstructured":"Brown JA, Amstutz A, Nsakala BL, Seeburg U, Vanobberghen F, Muhairwe J, et al. Extensive drug resistance during low-level HIV viraemia while taking NNRTI-based ART supports lowering the viral load threshold for regimen switch in resource-limited settings: a pre-planned analysis from the SESOTHO trial. J Antimicrob Chemother. 2021;76:1294\u20138.","journal-title":"J Antimicrob Chemother"},{"key":"743_CR100","doi-asserted-by":"crossref","unstructured":"Wensing AM, Charpentier C, Calvez V, Ceccherini-Silberstein F, G\u00fcnthard HF, Jacobsen DM, et al. Utilizing HIV proviral DNA to assess for the presence of HIV drug resistance. Clin Infect Dis. 2025:ciaf161.","DOI":"10.1093\/cid\/ciaf161"},{"key":"743_CR101","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1186\/s12879-022-07417-z","volume":"22","author":"P Liu","year":"2022","unstructured":"Liu P, You Y, Liao L, Feng Y, Shao Y, Xing H, et al. Impact of low-level viremia with drug resistance on CD4 cell counts among people living with HIV on antiretroviral treatment in China. BMC Infect Dis. 2022;22:426.","journal-title":"BMC Infect Dis"},{"key":"743_CR102","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.18099","volume":"3","author":"MM McLaughlin","year":"2020","unstructured":"McLaughlin MM, Ma Y, Scherzer R, Rahalkar S, Martin JN, Mills C, et al. Association of viral persistence and atherosclerosis in adults with treated HIV infection. JAMA Netw Open. 2020;3:e2018099.","journal-title":"JAMA Netw Open"},{"key":"743_CR103","doi-asserted-by":"crossref","unstructured":"Morton ZP, Mehta CC, Wang T, Palella FJ, Naggie S, Golub ET, et al. Cumulative HIV-1 viremia is associated with increased risk of multimorbidity among U.S. women living with HIV, 1997-2019. Open Forum Infect Dis. 2022:ofac702.","DOI":"10.1093\/ofid\/ofac702"},{"key":"743_CR104","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/j.chom.2020.03.014","volume":"27","author":"LB Cohn","year":"2020","unstructured":"Cohn LB, Chomont N, Deeks SG. The biology of the HIV-1 latent reservoir and implications for cure strategies. Cell Host Microbe. 2020;27:519\u201330.","journal-title":"Cell Host Microbe"},{"key":"743_CR105","doi-asserted-by":"publisher","DOI":"10.1111\/aji.13680","volume":"89","author":"AM Powell","year":"2023","unstructured":"Powell AM, Persaud D, Anderson JR, Kacanek D, Huo Y, Psoter K, et al. Markers of intestinal immune activation and inflammation are not associated with preterm birth among women with low level HIV viremia. American J Rep Immunol. 2023;89:e13680.","journal-title":"American J Rep Immunol"},{"key":"743_CR106","doi-asserted-by":"publisher","first-page":"2079","DOI":"10.1093\/cid\/ciaa413","volume":"72","author":"O Elvstam","year":"2021","unstructured":"Elvstam O, Marrone G, Medstrand P, Treutiger CJ, S\u00f6nnerborg A, Gissl\u00e9n M, et al. All-cause mortality and serious non-AIDS events in adults with low-level human immunodeficiency virus viremia during combination antiretroviral therapy: results from a Swedish nationwide observational study. Clin Infect Dis. 2021;72:2079\u201386.","journal-title":"Clin Infect Dis"},{"key":"743_CR107","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1097\/QAI.0b013e318258c651","volume":"60","author":"S Zhang","year":"2012","unstructured":"Zhang S, Van Sighem A, Kesselring A, Gras L, Smit C, Prins JM, et al. Episodes of HIV viremia and the risk of non-AIDS diseases in patients on suppressive antiretroviral therapy. JAIDS Journal of Acquired Immune Deficiency Syndromes. 2012;60:265\u201372.","journal-title":"JAIDS Journal of Acquired Immune Deficiency Syndromes."},{"key":"743_CR108","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.1097\/QAD.0000000000003240","volume":"36","author":"O Elvstam","year":"2022","unstructured":"Elvstam O, Marrone G, Engstr\u00f6m G, Nilsson PM, Carlander C, Treutiger CJ, et al. Associations between HIV viremia during antiretroviral therapy and cardiovascular disease. AIDS. 2022;36:1829\u201334.","journal-title":"AIDS."},{"key":"743_CR109","doi-asserted-by":"crossref","unstructured":"Ganesan A, Hsieh H-C, Chu X, Colombo RE, Berjohn C, Lalani T, et al. Low level viremia is associated with serious non-AIDS events in people living with HIV. Open Forum Infect Dis. 2024:ofae147.","DOI":"10.1093\/ofid\/ofae147"},{"key":"743_CR110","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1111\/hiv.13320","volume":"24","author":"H Yu","year":"2023","unstructured":"Yu H, Yang Y, Cao D, Zhao Y, Jin C, Sun H, et al. Association of low-level viremia with mortality among people living with HIV on antiretroviral therapy in Dehong, Southwest China: a retrospective cohort study. HIV Medicine. 2023;24:37\u201345.","journal-title":"HIV Medicine."},{"key":"743_CR111","doi-asserted-by":"publisher","first-page":"2812","DOI":"10.3390\/jcm11102812","volume":"11","author":"S Botha-Le Roux","year":"2022","unstructured":"Botha-Le Roux S, Elvstam O, De Boever P, Goswami N, Magnusson M, Nilsson P, et al. Cardiovascular profile of south African adults with low-level viremia during antiretroviral therapy. JCM. 2022;11:2812.","journal-title":"JCM."},{"key":"743_CR112","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1111\/hiv.12756","volume":"20","author":"O Elvstam","year":"2019","unstructured":"Elvstam O, Medstrand P, Jansson M, Isberg P, Gissl\u00e9n M, Bj\u00f6rkman P. Is low-level HIV -1 viraemia associated with elevated levels of markers of immune activation, coagulation and cardiovascular disease? HIV Med. 2019;20:571\u201380.","journal-title":"HIV Med"},{"key":"743_CR113","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.ijid.2019.12.001","volume":"91","author":"J Han","year":"2020","unstructured":"Han J, Mu W, Zhao H, Hao Y, Song C, Zhou H, et al. HIV-1 low-level viremia affects T cell activation rather than T cell development in school-age children, adolescents, and young adults during antiretroviral therapy. Int J Infect Dis. 2020;91:210\u20137.","journal-title":"Int J Infect Dis"},{"key":"743_CR114","doi-asserted-by":"crossref","unstructured":"Levy M, Monroe A, Horberg M, Benator D, Castel A, the DC Cohort Executive Committee. Is low-level viraemia associated with serum lipid profiles among HIV controllers? HIV Medicine [Internet]. 2020 [cited 2024 Jun 28];21. Available from: https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/hiv.12856.","DOI":"10.1111\/hiv.12856"},{"key":"743_CR115","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.663843","volume":"12","author":"M Younas","year":"2021","unstructured":"Younas M, Psomas C, Reynes C, Cezar R, Kundura L, Portal\u00e8s P, et al. Residual viremia is linked to a specific immune activation profile in HIV-1-infected adults under efficient antiretroviral therapy. Front Immunol. 2021;12:663843.","journal-title":"Front Immunol"},{"key":"743_CR116","doi-asserted-by":"publisher","first-page":"e01436","DOI":"10.1128\/JVI.01436-18","volume":"93","author":"M Ros\u00e1s-Umbert","year":"2019","unstructured":"Ros\u00e1s-Umbert M, Llano A, Bellido R, Olvera A, Ruiz-Riol M, Rocafort M, et al. Mechanisms of abrupt loss of virus control in a cohort of previous HIV controllers. J Virol. 2019;93:e01436\u201318.","journal-title":"J Virol"},{"key":"743_CR117","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1007\/s40506-018-0158-8","volume":"10","author":"K Promer","year":"2018","unstructured":"Promer K, Karris MY. Current treatment options for HIV elite controllers: a review. Curr Treat Options Infect Dis. 2018;10:302\u20139.","journal-title":"Curr Treat Options Infect Dis"},{"key":"743_CR118","unstructured":"UNAIDS Data 2022 [Internet]. 2023 [cited 2023 Apr 14]. Available from: https:\/\/www.unaids.org\/en\/resources\/documents\/2023\/2022_unaids_data."},{"key":"743_CR119","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.27584","volume":"6","author":"LF Collins","year":"2023","unstructured":"Collins LF, Palella FJ, Mehta CC, Holloway J, Stosor V, Lake JE, et al. Aging-related comorbidity burden among women and men with or at-risk for HIV in the US, 2008-2019. JAMA Netw Open. 2023;6:e2327584.","journal-title":"JAMA Netw Open"},{"key":"743_CR120","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1093\/jac\/dkac056","volume":"77","author":"OT Bareng","year":"2022","unstructured":"Bareng OT, Moyo S, Zahralban-Steele M, Maruapula D, Ditlhako T, Mokaleng B, et al. HIV-1 drug resistance mutations among individuals with low-level viraemia while taking combination ART in Botswana. J Antimicrob Chemother. 2022;77:1385\u201395.","journal-title":"J Antimicrob Chemother"},{"key":"743_CR121","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1310\/hct1102-100","volume":"11","author":"NF \u00d6nen","year":"2010","unstructured":"\u00d6nen NF, Overton ET, Seyfried W, Stumm ER, Snell M, Mondy K, et al. Aging and HIV infection: a comparison between older HIV-infected persons and the general population. HIV Clin Trials. 2010;11:100\u20139.","journal-title":"HIV Clin Trials"},{"key":"743_CR122","doi-asserted-by":"publisher","first-page":"1787","DOI":"10.1093\/cid\/ciu701","volume":"59","author":"J Schouten","year":"2014","unstructured":"Schouten J, Wit FW, Stolte IG, Kootstra NA, van der Valk M, Geerlings SE, et al. Cross-sectional comparison of the prevalence of age-associated comorbidities and their risk factors between HIV-infected and uninfected individuals: the AGEhIV cohort study. Clin Infect Dis. 2014;59:1787\u201397.","journal-title":"Clin Infect Dis"},{"key":"743_CR123","doi-asserted-by":"crossref","unstructured":"Gallant J, Hsue PY, Shreay S, Meyer N. Comorbidities among US patients with prevalent HIV infection\u2014a trend analysis. J Infect Dis [Internet]. 2017; [cited 2023 Jan 5]; Available from: http:\/\/academic.oup.com\/jid\/advance-article\/doi\/10.1093\/infdis\/jix518\/4743770.","DOI":"10.1093\/infdis\/jix518"},{"key":"743_CR124","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1093\/cid\/ciaa204","volume":"72","author":"LF Collins","year":"2021","unstructured":"Collins LF, Sheth AN, Mehta CC, Naggie S, Golub ET, Anastos K, et al. The prevalence and burden of non-AIDS comorbidities among women living with or at risk for human immunodeficiency virus infection in the United States. Clin Infect Dis. 2021;72:1301\u201311.","journal-title":"Clin Infect Dis"},{"key":"743_CR125","doi-asserted-by":"publisher","first-page":"e2059","DOI":"10.1093\/cid\/ciaa1928","volume":"73","author":"LF Collins","year":"2021","unstructured":"Collins LF, Sheth AN, Mehta CC, Naggie S, Golub ET, Anastos K, et al. Incident non-AIDS comorbidity burden among women with or at risk for human immunodeficiency virus in the United States. Clin Infect Dis. 2021;73:e2059\u201369.","journal-title":"Clin Infect Dis"},{"key":"743_CR126","doi-asserted-by":"publisher","first-page":"ofab558","DOI":"10.1093\/ofid\/ofab558","volume":"8","author":"RA Pond","year":"2021","unstructured":"Pond RA, Collins LF, Lahiri CD. Sex differences in non-AIDS comorbidities among people with human immunodeficiency virus. Open Forum Infect Dis. 2021;8:ofab558.","journal-title":"Open Forum Infect Dis"},{"key":"743_CR127","doi-asserted-by":"publisher","first-page":"39","DOI":"10.3851\/IMP2323","volume":"18","author":"L Zheng","year":"2013","unstructured":"Zheng L, Bosch RJ, Chan ES, Read S, Kearney M, Margolis DM, et al. Predictors of residual Viraemia in patients on long-term suppressive antiretroviral therapy. Antivir Ther. 2013;18:39\u201343.","journal-title":"Antivir Ther"},{"key":"743_CR128","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1111\/j.1365-3083.2008.02184.x","volume":"68","author":"SR Ostrowski","year":"2008","unstructured":"Ostrowski SR, Katzenstein TL, Pedersen BK, Gerstoft J, Ullum H. Residual Viraemia in HIV-1-infected patients with plasma viral load \u2264 20 copies\/ml is associated with increased blood levels of soluble immune activation markers. Scand J Immunol. 2008;68:652\u201360.","journal-title":"Scand J Immunol"},{"key":"743_CR129","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1097\/QAI.0b013e3182895af4","volume":"63","author":"B Taiwo","year":"2013","unstructured":"Taiwo B, Hunt PW, Gandhi RT, Ellingson A, McKenna M, Jacobson JM, et al. CD8+ T-cell activation in HIV-1\u2013infected patients experiencing transient low-level viremia during antiretroviral therapy. JAIDS Journal of Acquired Immune Deficiency Syndromes. 2013;63:101\u20134.","journal-title":"JAIDS Journal of Acquired Immune Deficiency Syndromes."},{"key":"743_CR130","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1086\/427340","volume":"191","author":"SR Ostrowski","year":"2005","unstructured":"Ostrowski SR, Katzenstein TL, Thim PT, Pedersen BK, Gerstoft J, Ullum H. Low-level viremia and proviral DNA impede immune reconstitution in HIV-1\u2013infected patients receiving highly active antiretroviral therapy. J Infect Dis. 2005;191:348\u201357.","journal-title":"J Infect Dis"},{"key":"743_CR131","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1097\/QAI.0b013e3182745ab0","volume":"62","author":"S Reus","year":"2013","unstructured":"Reus S, Portilla J, S\u00e1nchez-Pay\u00e1 J, Giner L, Franc\u00e9s R, Such J, et al. Low-level HIV viremia is associated with microbial translocation and inflammation. JAIDS Journal of Acquired Immune Deficiency Syndromes. 2013;62:129\u201334.","journal-title":"JAIDS Journal of Acquired Immune Deficiency Syndromes."},{"key":"743_CR132","doi-asserted-by":"publisher","first-page":"e0305641","DOI":"10.1371\/journal.pone.0305641","volume":"19","author":"AJ Stam","year":"2024","unstructured":"Stam AJ, Groenewegen H, Vissink A, Wensing AMJ, Nijhuis M, Bierman WFW. Periodontal inflammation as a potential driver of HIV low level viremia. PLoS One. 2024;19:e0305641.","journal-title":"PLoS One"},{"key":"743_CR133","unstructured":"Aldredge A, Mehta CC, Lahiri CD, Alcaide ML, Anastos K, Brown TT, et al. Consequences of low-level viremia by sex among people with HIV in the United States. [cited 2024 Oct 27]. Available from: https:\/\/www.croiconference.org\/abstract\/consequences-of-low-level-viremia-by-sex-among-people-with-hiv-in-the-united-states\/."},{"key":"743_CR134","doi-asserted-by":"publisher","first-page":"e755","DOI":"10.1093\/cid\/ciac465","volume":"76","author":"LF Collins","year":"2023","unstructured":"Collins LF, Mehta CC, Palella FJ, Fatade Y, Naggie S, Golub ET, et al. The effect of menopausal status, age, and human immunodeficiency virus (HIV) on non-AIDS comorbidity burden among US women. Clin Infect Dis. 2023;76:e755\u20138.","journal-title":"Clin Infect Dis"},{"key":"743_CR135","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1097\/QAI.0000000000003158","volume":"92","author":"A Hachfeld","year":"2023","unstructured":"Hachfeld A, Atkinson A, Stute P, Calmy A, Tarr PE, Darling KEA, et al. Brief report: does menopause transition influence viral suppression and adherence in women living with HIV? JAIDS Journal of Acquired Immune Deficiency Syndromes. 2023;92:399\u2013404.","journal-title":"JAIDS Journal of Acquired Immune Deficiency Syndromes."},{"key":"743_CR136","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1093\/cid\/ciab873","volume":"75","author":"S Gianella","year":"2022","unstructured":"Gianella S, Rawlings SA, Dobrowolski C, Nakazawa M, Chaillon A, Strain M, et al. Sex differences in human immunodeficiency virus persistence and reservoir size during aging. Clin Infect Dis. 2022;75:73\u201380.","journal-title":"Clin Infect Dis"},{"key":"743_CR137","doi-asserted-by":"publisher","first-page":"19785","DOI":"10.7448\/IAS.17.4.19785","volume":"17","author":"C-Y Cheng","year":"2014","unstructured":"Cheng C-Y, Luo Y-Z, Wu P-Y, Liu W-C, Yang S-P, Zhang J-Y, et al. Antiretroviral therapy (ART) management of low-level viremia in Taiwan (ALLEVIATE). J Int AIDS Soc. 2014;17:19785.","journal-title":"J Int AIDS Soc"},{"key":"743_CR138","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1000321","volume":"7","author":"RT Gandhi","year":"2010","unstructured":"Gandhi RT, Zheng L, Bosch RJ, Chan ES, Margolis DM, Read S, et al. The effect of raltegravir intensification on low-level residual viremia in HIV-infected patients on antiretroviral therapy: a randomized controlled trial. PLoS Med. 2010;7:e1000321.","journal-title":"PLoS Med"},{"key":"743_CR139","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1086\/650749","volume":"50","author":"D McMahon","year":"2010","unstructured":"McMahon D, Jones J, Wiegand A, Gange SJ, Kearney M, Palmer S, et al. Short-course raltegravir intensification does not reduce persistent low-level viremia in patients with HIV-1 suppression during receipt of combination antiretroviral therapy. Clin Infect Dis. 2010;50:912\u20139.","journal-title":"Clin Infect Dis"},{"key":"743_CR140","doi-asserted-by":"publisher","first-page":"e0001797","DOI":"10.1371\/journal.pgph.0001797","volume":"3","author":"N Nanyeenya","year":"2023","unstructured":"Nanyeenya N, Siu G, Kiwanuka N, Makumbi F, Nasuuna E, Nakanjako D, et al. Hopes, joys and fears: meaning and perceptions of viral load testing and low-level viraemia among people on antiretroviral therapy in Uganda: a qualitative study. PLOS Glob Public Health. 2023;3:e0001797.","journal-title":"PLOS Glob Public Health"}],"container-title":["Current HIV\/AIDS Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11904-025-00743-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11904-025-00743-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11904-025-00743-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T14:04:33Z","timestamp":1769609073000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11904-025-00743-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,26]]},"references-count":140,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["743"],"URL":"https:\/\/doi.org\/10.1007\/s11904-025-00743-2","relation":{},"ISSN":["1548-3568","1548-3576"],"issn-type":[{"value":"1548-3568","type":"print"},{"value":"1548-3576","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,26]]},"assertion":[{"value":"22 April 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 June 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}],"article-number":"39"}}